Document is current
Any future updates will be listed below
-
Authors
Yamagishi, Makoto https://orcid.org/0000-0002-8142-4686
Kuze, Yuta
Kobayashi, Seiichiro
Nakashima, Makoto
Morishima, Satoko https://orcid.org/0000-0002-7391-4271
Kawamata, Toyotaka https://orcid.org/0000-0003-1311-8756
Makiyama, Junya https://orcid.org/0000-0003-0883-2920
Suzuki, Kako
Seki, Masahide https://orcid.org/0000-0001-6091-8698
Abe, Kazumi
Imamura, Kiyomi
Watanabe, Eri
Tsuchiya, Kazumi
Yasumatsu, Isao https://orcid.org/0009-0000-9865-4835
Takayama, Gensuke
Hizukuri, Yoshiyuki
Ito, Kazumi
Taira, Yukihiro
Nannya, Yasuhito
Tojo, Arinobu https://orcid.org/0000-0001-9016-1948
Watanabe, Toshiki
Tsutsumi, Shinji
Suzuki, Yutaka https://orcid.org/0000-0003-4852-1879
Uchimaru, Kaoru https://orcid.org/0000-0002-1665-9606
- License Information
-
More Information
Article History
Received: 6 July 2022
Accepted: 23 January 2024
First Online: 21 February 2024
Competing interests
: M.Y., Y.S. and K.U. received research funding from Daiichi Sankyo Co., Ltd. I.Y. is an employee of Daiichi Sankyo RD Novare Co., Ltd. G.T., Y.H., K.Ito and S.T. are employees of Daiichi Sankyo Co., Ltd. Daiichi Sankyo Co., Ltd holds substance patents on valemetostat. The University of Tokyo and Daiichi Sankyo Co., Ltd hold patents for application of valemetostat to patients with ATL and individuals infected with HTLV-1. M.Y. and T.W. are named as inventors. All other authors declare no competing interests.
